Expertise: Analgesia 9 results
Milena Kanova-Petrova, M.D.
Pain is a significant health problem that impacts quality of life and imparts high costs to society. Despite intense research effort and progress in our understanding of the mechanistic and molecular basis of pain, there have been few real breakthroughs...
Andreas Schreiner, M.D.
Placebo response is one of the most significant challenges faced by drug developers who are investigating new pain medications. According to a review of published chronic neuropathic pain trials, placebo responses have increased in magnitude over time, making it even...
The placebo effect can be problematic in analgesia clinical trials with a symptom-based approach, as placebo-related analgesic responses may occur and persist for some time in up to 60 percent of study participants.1 In chronic pain studies, it is generally...
The use of placebo control in clinical trials has long been a topic of spirited debate. Proponents maintain that placebo control is necessary for proving the safety and efficacy of investigational products. Critics argue that use of placebo sacrifices patient...
We were conducting a trial for a painful diabetic neuropathy (PDN) drug and were investigating why one site had an especially high placebo response rate. Then one of our representatives, waiting in the site’s lobby to meet with the principal...
Between 7 and 10 percent of the U.S. population suffers from some type of neuropathic pain, and a significant share of those affected require chronic pain treatment.1 This high rate of occurrence makes our limited understanding of these afflictions, and...